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STOP proteins are microtubule-associated, 
calmodulin-regulated proteins responsible 
for the high degree of stabilization 
displayed by neuronal microtubules. STOP 
suppression in mice induces synaptic defects 
affecting both short- and long-term synaptic 
plasticity, in hippocampal neurons. 
Interestingly, STOP has been identified as a 
component of synaptic structures in 
neurons, despite absence of microtubules in 
nerve terminals, indicating the existence of 
mechanisms able to induce a translocation 
of STOP from microtubules to synaptic 
compartments. Here we have tested STOP 
phosphorylation as a candidate mechanism 
for STOP relocalization. We show that, 
both in vitro and in vivo, STOP is 
phosphorylated by the multifunctional 
enzyme calcium/calmodulin-dependent 
protein kinase II (CaMKII), which is a key 
enzyme for synaptic plasticity. This 
phosphorylation occurs on at least two 
independent sites. Phosphorylated forms of 
STOP do not bind microtubules in vitro and 
do not co-localize with microtubules in 
cultured differentiating neurons. Instead, 
phosphorylated STOP co-localizes with 
actin assemblies along neurites or at 
branching points. Correlatively, we find 
that STOP binds to actin in vitro. Finally, in 
differentiated neurons, phosphorylated 
STOP co-localizes with clusters of synaptic 
proteins, whereas unphosphorylated STOP 
does not. Thus, STOP phosphorylation by 
CaMKII may promote STOP translocation 
from microtubules to synaptic 
compartments where it may interact with 
actin, which could be important for STOP 
function in synaptic plasticity. 
 
Microtubules are vital components of 
the cell cytoskeleton, being involved in cell 
mitosis, intracellular organization and cell 
morphogenesis. Neurons contain abundant 
subpopulations of stable microtubules that 
resist depolymerising conditions such as 
exposure to cold temperature and to 
depolymerizing drugs (1-3). In neurons, 
microtubule stabilization is mainly due to 
association with a family of proteins known as 
STOPs (Stable Tubule Only Polypeptides). 
STOP proteins were initially characterized as 
microtubule cold-stabilizing factors whose 
activity was inhibited by interaction with Ca2+-
calmodulin (4), and subsequent work has 
shown that STOPs contain bi-functional 
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modules comprised of overlapping 
calmodulin-binding and microtubule-
stabilizing sequences (5). Neurons contain two 
major variants of STOP, E-STOP (89 kD) and 
N-STOP (116 kD). E-STOP is present in mice 
brain from embryonic stage E16 to adulthood, 
whereas N-STOP appears at birth and is 
subsequently expressed in the adult brain (2,6). 
STOP function has been investigated in the 
whole animal by studying STOP null mice (7). 
In these mice, microtubule cold stability is 
suppressed, with no dramatic consequences for 
mouse organogenesis, viability or brain 
anatomy. However, STOP -/- mice display 
multiple synaptic deficits that affect both long- 
and short-term synaptic plasticity in the 
hippocampus. These synaptic defects are 
associated with depleted vesicular pools in 
glutamatergic nerve terminals and with severe 
behavioral disorders (8), which, interestingly, 
are specifically alleviated with long-term 
neuroleptic treatment. It has been very 
surprising that a protein associated with 
microtubules along whole neurites turns out to 
be important for glutamatergic synaptic 
function, despite apparent microtubule absence 
in nerve terminals. However, from proteomic 
analysis of synaptosomal fractions, there is 
evidence that STOP localizes to synapses (8,9) 
and this raises questions concerning the 
mechanisms that could promote STOP 
dissociation from microtubules and re-
localization in synaptic structures. Previous 
evidence has indicated that STOP can be 
inactivated by calmodulin-dependent 
phosphorylation (10), correlated with the 
presence of putative CaMKII phosphorylation 
sites in the STOP sequence (6). Interestingly, 
long-term potentiation (LTP), which is known 
to involve CaMKII, is severely impaired in 
STOP null mice (7). Here, we have tested both 
the occurrence and the consequences of STOP 
phosphorylation. We show that CaMKII 
phosphorylates STOP on at least two 
independent sites (S198, S491), both in vitro 
and in vivo. Consequently, phosphorylated 
STOPs do not bind to microtubules in vitro. 
Additionally, the phosphorylated forms of 
STOP co-localize with actin-rich structures in 
cultured neurons and bind to polymerized actin 
in vitro. Finally, phosphorylated STOP protein 
associates with synaptic markers following 
synaptogenesis, in cultured neurons. Thus, 
phosphorylation by CaMKII may delocalize 
STOPs from microtubules and allow STOP 
association with synaptic actin, which may be 
important for synaptic plasticity. 
 
EXPERIMENTAL PROCEDURES 
 
Purification of STOP and CaMKII from mouse 
brain (CE fraction) - Purification of STOP 
protein from adult mice brain was performed 
as described by Pirollet et al. (11). All buffers 
used during STOP purification contained 2 
mM DTT and protease inhibitors (1 mM 
PMSF, 104 units/ml aprotinin; 20 µM 
leupeptin). Briefly, 40 brains from OF1 mice 
were homogenized in MEM buffer (100 mM 
Mes, 1 mM MgCl2, 1 mM EGTA, pH 6.75) 
and centrifuged at 100,000 g for 40 min at 4° 
C. The supernatant was loaded on a 
Sepharose-S Fast Flow column and bound 
proteins were eluted in MEM containing 0.4 M 
NaCl. The eluate was adjusted to 2 mM 
calcium and passed through a calmodulin-
agarose column equilibrated in MEM buffer 
containing 2 mM CaCl2 / 0.4 M NaCl. Bound 
proteins were eluted in MEM buffer 
containing 0.4 M NaCl and 1 mM EGTA. The 
purified fraction (calcium eluate, CE) was 
stored in elution buffer containing 10% 
glycerol, at -80° C. 
Phosphorylation reaction - CE fraction 
containing STOPs was buffer-exchanged to 50 
mM Pipes, 10 mM MgCl2, pH 7.0. The 
phosphorylation reaction was performed in the 
presence of 100 µM ATP (added of 2 µCi 
γ−32P-ATP when indicated), 0.7 mM CaCl2, 
0.3 µM calmodulin, 0.4 mM EGTA, 0.5 µM 
mycrocystine, 1 µM okadaic acid and 5 mM 2-
mercapto-ethanol, during 30 min at 30° C. For 
quantitative experiments, gels were dried 
before exposure on a screen for analysis with a 
phosphorimager (Molecular Imager® FX, 
Biorad). Relative amounts of incorporated 
radioactivity were quantified using Quantity 
One® software (Biorad). For control 
experiments, the buffer-exchanged CE fraction 
was incubated with alkaline phosphatase for 
30 min at 37° C, resulting in de-
phosphorylation of STOPs. For experiments 
using pre-activated CaMKII, CE fraction was 
incubated with 30 µM calmodulin and 0.7 mM 
calcium for 10 minutes at 30° C. 
Phosphorylation reaction was then performed 
in the presence or in the absence of 2.5 mM 
EGTA at 30° C for 30 minutes.  
Phospho-STOP antibodies and primary 
antibodies - Rabbit polyclonal antibodies were 
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raised against phospho-synthetic peptides 
corresponding to the potential phosphorylated 
sites in N-STOP protein, as shown in figure 
1A. The phospho peptides P1 to P4 used for 
the immunisation were the following: 
RPRpSEYQPSDAPFC (aa 136-148); 
RPQpSQERGPMQLC (aa 195-206); 
RAWpTDIKPVKPIKC (aa 435-447); 
RRIRpSLYSEPFKEC (aa 487-499), according 
to aa numbering of mouse N-STOP (GenBank 
Accession number CAA75930). These 
peptides were used to generate sera P1, P2, P3 
and P4 respectively (Eurogentec). The C-
terminal cystein residue of each peptide was 
introduced for the purification steps. Crude 
sera were affinity-purified against the 
phosphorylated peptide on Sulfolink coupling 
gel (Pierce). Antibodies were eluted with 100 
mM glycine, pH 2.5, neutralised with Tris 1 
M, pH 8.0 and then incubated for 1 h with the 
corresponding non-phosphorylated peptide 
coupled on Sulfolink gel in order to absorb 
antibodies reacting with non-phosphorylated 
peptides. Polyclonal antibodies reacting only 
with phosphorylated peptides were collected in 
the flow-through and stored at -80° C in 50% 
glycerol. Affinity-purified P2 and P4 
polyclonal antibodies did not show detectable 
cross reactivity in enzyme-linked 
immunoabsorbent assay (ELISA) tests (not 
shown). The same phospho-peptides P1-P4 
were used to generate monoclonal antibodies 
following standard procedure. Hybridoma 
culture supernatants were screened for anti 
STOP phospho-peptides using ELISA assay. 
The positive hybridomas were selected and 
screened on western blot for immunoreactivity 
on phosphorylated and non-phosphorylated 
STOP proteins. Positives hybridomas were 
sub-cloned by limiting dilution. 
The following primary antibodies were used in 
this study : mAb against α-tubulin (alpha3a 
clone (12), ascitic fluid, dilution 1/1,000 for 
IF); mAb 175 against C-terminal part of N-
STOP (6) (dilution 20 µg/ml for IF and 1 
µg/ml for WB); affinity-purified phospho-
STOP P2 and P4 antibodies (dilution 20 µg/ml 
for IF and 1 µg/ml for WB); P1 mAb against 
phospho-STOP (hybridoma culture 
supernatant, dilution 1/10 for WB); mAb 
against CaMKII (Ref C89220, Transduction 
laboratories), Homer (all isoforms, Chemicon), 
synapsin1 (BD Biosciences), CaMKI and 
CaMKIV (Santa Cruz Biotech.) were used 
following manufacturer’s advice. 
Sedimentation of STOPs with microtubules or 
actin - All proteins were pre-clarified at 
150,000 g for 15 minutes in a TL-100 
ultracentrifuge (Beckman) at 4° C prior start 
experiments. STOP proteins of the CE fraction 
were either phosphorylated by CaMKII or 
dephosphorylated with alkaline phosphatase 
treatment as described above. Microtubule-
binding assay was performed as in Masson and 
Kreis (13) using taxol-stabilized microtubules 
(4 µM) as substrates. Actin-binding assay was 
performed with CE fraction containing 0.5 µM 
phospho or de-phospho STOP (as estimated on 
Coomassie blue gels, using known amounts of 
pure STOP as standards) complemented or not 
with various amount of G-actin (1 µM, 6 µM 
and 15 µM), in 100 µl of a 1x F-
polymerization buffer (10X stock: 50 mM 
Tris-HCl, 5 mM DTT, 5 mM ATP, 1 M KCl, 
50 mM MgCl2, pH 7.5) in the presence of 1 
mM EGTA. After 90 min of incubation at 22° 
C, samples were centrifuged at 150,000 g for 
15 minutes at 4° C. Supernatants were 
removed and kept; the pellets were washed 
twice with polymerization buffer and 
dissolved in 100 µl of H20. Laemmli buffer 
was added to the pellet solutions and to the 
supernatants. Equal amounts of each sample 
were separated by 7.5% SDS PAGE and either 
stained with Commassie blue or transferred on 
nitrocellulose and blotted with mAb 175 or 
CaMKII antibodies. 
Cell culture - Hippocampal cell cultures were 
prepared according to Dotti et al. (14). Briefly, 
mouse hippocampi (E18.5) were removed and 
digested in 0.25% trypsin in HBSS 
(Invitrogen) at 37° C for 15 min. After manual 
dissociation, cells were plated at a 
concentration of 5,000–15,000 cells/cm2 on 
poly-L-lysine (Sigma) coated coverslips in 
DMEM-10% FBS (Invitrogen). One hour after 
plating, the medium was changed to DMEM 
containing B27 and N2 supplement 
(Invitrogen). Inhibitor of CaMKII, KN62 (5 
µM) was applied to neuronal culture for 8 h 
prior to cell fixation when indicated. In some 
experiments, neuronal cultures were subjected 
to cytochalasin treatment (50 µM, for 10 min). 
In some experiments, neurons in culture were 
activated by exposure to glutamate treatment 
(glutamate 100 µM, glycine 10 µM) for 15 
min prior to fixation.  
Immunofluorescence - Neurons grown on 
coverslips for 12 to 30 days were fixed 20 min 
with warmed solution of 4% 
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paraformaldehyde, 0.12 M sucrose, in PBS, 
pH 7.4 and then permeabilized for 3 min using 
0.2% Triton X100, in PBS, pH 7.4. Cells were 
processed for immunofluorescence by 
incubation with primary antibodies for 1 h in 
PBS, 0.2 % Tween 20 and then with secondary 
antibodies (Cy3- or Alexa488-coupled from 
Molecular probes and Jackson Immuno-
research, respectively) for 40 min. To visualize 
F-actin, rhodamine-phalloidin (Molecular 
Probes) was included with the secondary 
antibodies. The cells were analyzed with an 
inverted microscope. Images were digitalized 
using a Princeton RTE-CCD-1317-K/1 camera 
(Princeton Instruments) and IPLab Spectrum 
software (Signal Analytics). 
 
RESULTS 
 
CaMKII Phosphorylation sites in N-STOP - 
The consensus aa sequence for CaMKII 
phosphorylation is K/R X X S/T, where either 
S or T residues are phosphorylated (15). A 
search for such sequences in murine N-STOP 
protein sequence (Genbank Accession number 
CAA75930) revealed four candidate sequences 
(P1 to P4, Figure 1A) containing serine or 
threonine residues S139, S198, T438 and 
S491, respectively. N-STOP contains two 
classes of microtubule-stabilizing modules, 
Mc and Mn and multiple calmodulin-binding 
sites (5). The locations of P1-P4 sites relative 
to these STOP functional domains (5) is 
shown in Figure 1A. All four P1-P4 sequences 
are located within or are overlapping a 
calmodulin-binding site on N-STOP. P1 and 
P3 are located into or are overlapping with 
microtubule-stabilizing modules Mn1 and 
Mn3, respectively. 
STOP phosphorylation by CaMKII in vitro - 
We used semi-purified fractions to assay 
STOP protein phosphorylation in vitro. These 
protein fractions (CE fractions) were purified 
from mouse brain extracts by ion exchange 
chromatography followed by calmodulin 
affinity chromatography. The procedure 
resulted in the isolation of several calmodulin-
binding proteins as shown on SDS gels in 
figure 1B. CE fractions contained one major 
band at 116 KD and one other prominent band 
at 52 KD band. According to immunoblots of 
CE fraction, with anti N-STOP antibody 
(Figure 1C) and with anti CaMKII antibody 
(Figure 1D) the 116 KD band corresponded to 
N-STOP, and the 52 KD and 58 KD bands to 
subunits of CaMKII. Thus, CE fractions 
contained both N-STOP and CaMKII. CE 
fractions were also immuno-blotted with anti 
CaMKI and CaMKIV antibodies with negative 
results (not shown). 
Incubation of CE fraction proteins with γ−32P-
ATP in the absence of Ca2+-calmodulin 
followed by SDS PAGE analysis and 
autoradiography showed little phosphate 
incorporation in the bands corresponding to N-
STOP or to CaMKII (Figure 1E, left column). 
Phosphate incorporation was dramatically 
enhanced in the presence of Ca2+-calmodulin 
with an apparent shift of phosphorylated 
bands, which migrated at positions 
corresponding to higher apparent molecular 
weights (Figure 1E, right column). Band shift 
of both N-STOP and CaMKII following 
phosphorylation was confirmed on 
immunoblots (Figure 1F). The whole N-STOP 
band was shifted, showing that all STOP 
molecules had been phosphorylated during the 
phosphorylation reaction. 
In a time course analysis of STOP 
phosphorylation (Figures 1 G and H), STOP 
phosphorylation reached a plateau within 10 
minutes. After one minute of incubation, a 
small shift of N-STOP was detectable (Figure 
1H), showing that STOP molecules had 
already incorporated at least one molecule of 
phosphate at this time point. According to 
quantitative autoradiography, the ratio of 
phosphate incorporation in N-STOP at the 
plateau versus phosphate incorporation at 1 
minute was circa 3.7. Assuming that the first 
shift corresponds to the incorporation of a 
single phosphate group in STOP molecules, 
this ratio may reflect the phosphorylation of 
the four CaMKII phosphorylation consensus 
sites at the plateau. 
We used purified N-STOP and pure CaMKII 
to test whether N-STOP was truly a substrate 
for CaMKII. We observed both N-STOP 
phosphorylation and shift following STOP 
phosphorylation with CaMKII (Supplementary 
figure S1). However, pure STOP is hard to 
prepare in biochemical amounts and cannot be 
stored, hence all subsequent experiments were 
run using CE fractions. 
High concentrations of Ca2+/calmodulin 
inhibit STOP phosphorylation by CaMKII - 
The overlap of all P1-P4 putative STOP 
phosphorylation sites with calmodulin-binding 
sites on N-STOP (Figure 1A) raised the 
possibility of an inhibition of STOP 
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phosphorylation through steric hindrance, in 
the presence of an excess of Ca2+-calmodulin 
complex. We examined STOP 
phosphorylation in CE extracts in the presence 
of varying amounts of calmodulin ranging 
from 0.003 to 30 µM. Full activation of 
CaMKII occurred for calmodulin 
concentrations above 0.03 µM as indicated by 
the band shift of CaMKII specific (Figure 2A). 
STOP phosphorylation was also observed 
above 0.03 µM calmodulin as indicated by the 
shift of N-STOP molecular weight on western 
blots (Figure 2A). However, at calmodulin 
concentrations above 0.3 µM, there was a 
small but reproducible decrease in N-STOP 
shift, indicating inhibition of N-STOP 
phosphorylation by calmodulin in the 
micromolar range. 
When CaMKII is pre-activated through 
autophosphorylation in the presence of Ca2+-
calmodulin, the enzyme remains activated 
following Ca2+ removal, as long as 
dephosphorylation does not occur. We made 
use of this persistent CaMKII activation for 
further test the inhibition of N-STOP 
phosphorylation by Ca2+-calmodulin 
complexes. Pre-activated CaMKII was added 
to CE fractions, in the presence of 30 µM 
Ca2+-calmodulin, and in the presence or in the 
absence of EGTA (Figure 2B) in order to 
inactivate or not the Ca2+-calmodulin 
complexes. The N-STOP band shift was 
markedly reduced in the absence of EGTA 
(active Ca2+-calmodulin complex) compared to 
the band shift observed in the presence of 
EGTA (no active Ca2+-calmodulin complex). 
Altogether these results show that CaMKII-
mediated STOP phosphorylation is inhibited 
by Ca2+-calmodulin binding to N-STOP, 
compatible with an overlap of P1-P4 with 
calmodulin-binding sites, on the N-STOP 
sequence. 
Phosphorylated N-STOP does not bind to 
microtubules in vitro - We next investigated 
whether the phosphorylation of STOP by 
CaMKII could affect STOP binding to 
microtubules, as phosphorylation often 
regulates the binding on microtubules of 
associated proteins (16,17). CE fractions, with 
or without prior phosphorylation, were mixed 
with taxol-stabilized microtubules. 
Microtubules were then pelleted and the STOP 
content of both supernatant and pellet was 
analyzed on immunoblots. In the absence of 
phosphorylation, STOP co-sedimented with 
microtubules, being present in microtubule 
pellets and absent in supernatants (Figure 3, 
lanes 1-2). In contrast, phosphorylated STOP 
was absent in microtubule pellets, being only 
present in the supernatants (Figure 3, lanes 5-
6). Thus, phosphorylated STOP does not bind 
to microtubules in vitro indicating a strong 
regulation by CaMKII of the STOP binding to 
microtubule in vivo. 
Phosphorylated STOP antibodies - We 
designed phospho-peptides corresponding to 
the four potential CaMKII phosphorylation 
sequences on STOP (P1 to P4, figure 1A) and 
used them to produce polyclonal or 
monoclonal antibodies specific to 
phosphorylated forms of STOP. On western 
blots of CE fractions, P2 and P4 polyclonal 
antibodies reacted with N-STOP (Figure 4). 
The signal was strongly enhanced when a 
phosphorylation step was introduced prior to 
immunoblotting and was erased when CE 
fractions were exposed to alkaline phosphatase 
(Figure 4). Additionally we obtained a 
monoclonal antibody P1, which reacted only 
very weakly with N-STOP in CE fractions 
whereas a strong signal was observed when a 
phosphorylation step was introduced prior to 
immunoblotting (Figure 4). These results 
indicate that at least three out of the four P1-
P4 peptides are phosphorylated by CaMKII in 
vitro, at S139, S198 and S491 positions. 
Additionally, the immuno-reactivity of P2 and 
P4 antibodies on native CE fractions indicates 
the presence of phosphorylated STOP protein 
in adult brain extract. This strongly suggests 
that STOP is phosphorylated at least on S198 
and S491 residues in vivo.  
Phosphorylated STOP co-localizes with actin-
rich structures in differentiating neurons - We 
used one of the polyclonal phospho-STOP 
antibody, P2 antibody and N-STOP 
monoclonal antibody to localize 
phosphorylated STOP and total N-STOP in 
neuronal cells. 
Specificity of P2 antibody for STOP labeling 
in neuronal culture was assessed by staining 
wild type and STOP deficient neurons 
(Supplementary figure S2). Hippocampal 
neurons from E18.5 embryos were cultured for 
12 days in vitro, a stage of differentiation at 
which N-STOP is expressed. At this stage of 
differentiation neurons are forming a complex 
network comprising neurite extensions and 
branching points (18) where individual 
microtubules are distinct. Total N-STOP 
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labeling showed co-localization of STOP and 
tubulin staining in neurites (Figure 5A, upper 
left panels) whereas phosphorylated STOP 
staining using P2 antibody showed a diffuse 
staining, not co-localizing with tubulin 
staining and concentrated in spike-like 
structures appended to neurites (Figure 5A, 
bottom left panels). At branching points, N-
STOP staining again co-localized with 
microtubules (Figure 5A, upper right panels). 
In contrast, P2 labeling was concentrated in a 
ring-shaped zone, underneath the cell 
membrane, not co-localized with microtubules 
(Figure 5A, bottom right panels). Since 
neuronal actin concentrates in spikes along 
neurites and in sub-membrane domains at 
branching points (18), we investigated the 
possibility of a co-localisation of 
phosphorylated STOP with actin. P2 antibody 
staining co-localized with acting staining in 
spikes (Figure 5B, bottom left panels). At 
branching points, P2 stained the internal 
border of the actin rich extensions (Figure 5B, 
bottom right panels). Interestingly, 
cytochalasin treatment, which results in a 
disorganization of the actin network, also 
induced a loss of P2 staining indicating an 
association of phosphorylated STOP with F-
actin assemblies (Figure 5C). When neurons 
were activated by a 15 min exposure to 
glutamate prior to fixation, the P2 staining of 
spikes increased two fold, compatible with 
CaMKII activation and enhanced STOP 
phosphorylation (Figure 5D). CaMKII 
phosphorylations sites can be substrate for the 
cyclic AMP regulated protein kinases PKA, 
which is also present in synapses and is 
involved in synaptic plasticity (19). PKA is 
insensitive to the general CaMkinases inhibitor 
KN62. In neuronal cells, exposure to KN62 
suppresses the P2 staining, indicating 
inhibition of STOP phosphorylation (Figure 
5E). This result argues against a significant 
contribution of PKA in STOP 
phosphorylation, in vivo. 
We then tested whether STOP could interact 
directly with polymeric actin in vitro, using 
standard sedimentation assays. CE STOP 
fractions, either phosphorylated or treated with 
alkaline phosphatase, were mixed with actin 
under polymerizing conditions. Then, 
polymerized actin was pelleted and STOP 
content was analyzed on immunoblots, in both 
supernatants and pellets (Figure 6). The 
concentrations of F-actin at which 
approximately half of STOP co-sedimented 
with actin were of circa 1 µM and 6 µM for 
un-phosphorylated and phosphorylated STOP, 
respectively (Figure 6B-C). In the same 
sedimentation assays, CaMKII co-sedimented 
with F-actin when non-phosphorylated, 
whereas phosphorylated CaMKII remained in 
the supernatants, as expected from previous 
study (20). Affinity purified STOP fractions, 
devoid of detectable amounts of CaMKII also 
bound to F-actin (Figure 6B), indicating that 
actin binding is a genuine property of STOP. 
These results indicate that STOP and 
phosphorylated STOP both interacts directly 
with polymerized actin in vitro, although with 
different Kds.  
Phosphorylated forms of STOP co-localize 
with clusters of synaptic proteins in 
differentiated neurons - Hippocampal neurons 
were cultured for 45 days in vitro, a stage of 
differentiation at which neurons are forming a 
complex network and are connected by 
synapses. In such cultures, synaptic proteins 
form clusters. Clusters corresponding to 
different synaptic proteins are both present in 
transport vesicles and at synapses. In 
differentiated neurons, the presynaptic vesicle-
associated protein synapsin and the post-
synaptic PSD-associated protein homer, 
showed a typical cluster distribution (Figure 
7). As these markers, phosphorylated STOP 
(STOP-P) was distributed in clusters and 
phosphorylated STOP staining partially 
overlapped with synapsin or homer stainings 
(Figure 7, arrows). This overlap was never 
observed with N-STOP. Hence, these results 
are compatible with a presence of 
phosphorylated STOP in both the pre- and 
post-synaptic compartments. 
 
DISCUSSION 
 
STOP proteins are important for synaptic 
plasticity, as demonstrated by the synaptic 
defects in both long- and short-term plasticity 
exhibited by STOP deficient mice (8). Given 
the apparent absence of microtubules in nerve 
terminals, it has been surprising to find a 
synaptic function for a protein tightly 
associated with microtubules in neurites (2). 
STOP function in synaptic plasticity may arise 
indirectly from modifications of microtubule 
dynamics and their resulting downstream 
effects on synaptic functions (7). However, 
there are indications for a synaptic localization 
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of STOPs which are present in synaptosomal 
fractions (8) and in the PSD proteome (9). 
Here, we find that CaMKII, which is a key 
enzyme for synaptic plasticity (21,22), can 
inhibit STOP binding to microtubules through 
phosphorylation, thereby offering a possible 
mechanism for persistent STOP dissociation 
from microtubules and localization in other 
compartments, during synaptic activation. N-
STOP is phosphorylated by CaMKII in vitro 
on at least three independents sites (S139, 
S198 and S491) out of four consensus CaMKII 
phosphorylation sites, in the sequence. 
Previous studies have shown that N-STOP 
interaction with microtubules can be inhibited 
by direct Ca2+-calmodulin binding to 
microtubules (4). These data suggest a model 
in which N-STOP dissociates from 
microtubules in two separate ways, either by 
binding Ca2+-calmodulin in response to 
transient Ca2+ influxes induced by synaptic 
activation, or through phosphorylation by 
active CaMKII, in the absence of Ca2+-
calmodulin. The latter mechanism could be 
particularly relevant during short or long term 
synaptic potentiations, which both involve 
active CaMKII, after the Ca2+ peak dropped 
back to basal levels. 
In cultured neurons, we find that 
phosphorylated STOP co-localizes with actin 
spikes along neurites and at branching points 
during differentiation. We also find that both 
phosphorylated and non-phosphorylated forms 
of STOP bind to polymerized actin in vitro. 
although phosphorylated STOP has apparently 
less affinity for F-actin. In cells, the overall 
concentration of F-actin is circa 100µM (23), 
higher than the F-actin concentrations found to 
absorb both dephosphorylated and 
phosphorylated STOP quantitatively, in vitro 
(6 µM and 16 µM, respectively). Additionally, 
local F-actin concentrations in cellular actin 
assemblies are much higher than 100 µM, so 
high in fact, that once bound to F-actin, actin-
binding proteins do not dissociate measurably 
from actin assemblies. Dissociation requires 
actin disassembly (23). In this context, our 
data suggest a model in which phosphorylated 
STOP, which has no detectable affinity for 
microtubules, binds to F-actin. Subsequent 
STOP dephosphorylation could re-enforce the 
interaction between STOP and F-actin, without 
causing STOP re-association with 
microtubules, as long as F-actin does not 
depolymerize. 
It is uncertain whether STOP binding to actin 
at actin spikes or at branching points is 
important physiologically since we have not 
detected any obvious perturbation of neurite 
morphogenesis in STOP null mice (7). A 
major signature of STOP inactivation, is a 
dramatic depletion of synaptic vesicle pools in 
glutamatergic synapses, which could be central 
to some of the synaptic disorders observed in 
STOP null mice (8). Actin is important for the 
localization and regulation of synaptic vesicle 
pools and binding to actin may be important 
for STOP effect on the size of vesicular pool 
(24-28). Additionally, there is evidence for a 
burst of actin polymerization during synaptic 
potentiation, both in the pre- and post-synaptic 
compartments (24,27,29,30), and we find 
phosphorylated STOP in the vicinity of pre- 
and post-synaptic protein clusters, in 
differentiated neurons. Finally, cross talks 
between microtubule and actin assemblies 
have been a subject of great interest in recent 
times and several proteins with dual 
microtubule / actin binding properties have 
been identified as crucial integrators of the 
cytoskeleton (31-33). Our findings suggest that 
STOP protein may function as such integrators 
in nerve terminals. 
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FIGURE LEGENDS 
 
Fig. 1. Phosphorylation of N-STOP by CaMKII. A, Schematic representation of mouse N-STOP 
protein showing the location and sequences of the four peptides P1 to P4, containing potential 
CaMKII phosphorylation sites. Phosphorylable serine or threonine residues of P1 to P4, (S139, S198, 
T438 and S491, respectively) are in red. Note that all the phosphorylation sites are overlapping with 
calmodulin-binding sites (underlined residues). Mc and Mn modules are microtubule-binding sites. B, 
Purified proteins from brain extract after ion exchange and calmodulin affinity chromatography (CE 
fraction) on Commassie blue-stained SDS-PAGE gel. C-D, Western blot and immuno-detection of 
mouse N-STOP (116 kD)(C) and of CaMKII protein (52 kD and a doublet at 58 kD)(D) in CE 
fraction using antibody mAb 175 against N-STOP and anti CaMKII antibody, respectively. E-F, In 
vitro phosphorylation of N-STOP by CaMKII. Phosphorylation reaction was performed using CE 
fraction with γ−32P-ATP in the presence or in the absence of Ca2+. Samples were analyzed by 
SDS/PAGE and either autoradiography or western blot. (E) Autoradiogram showing 32P-ATP 
incorporation, indicating auto-phosphorylation of CaMKII (apparent molecular weights of 55 and 60 
kD, stars) and phosphorylation of N-STOP (apparent molecular weight of 125 kD, star). (F) Western 
blot analysis of CaMKII and STOP with antibodies as in (C) and (D). Note that in the presence of 
Ca2+ and ATP the phosphorylation of both CaMKII and N-STOP produces a shift of their molecular 
weight. G-H, Time course of STOP phosphorylation, analyzed by 32P autoradiogram (G) and by 
Western blot (H), using antibodies as in (C). 
 
Fig. 2. Effect of calmodulin on N-STOP phosphorylation by CaMKII. A, Phosphorylation reaction in 
CE fraction was performed with various concentration of calmodulin, ranging from 0 to 30 µM, in the 
presence or in the absence of Ca2+. Proteins of the phosphorylation reaction were separated by SDS 
PAGE and analyzed by Western blot using N-STOP antibody mAb 175 and anti CaMKII antibody. B, 
CaMKII was pre-activated in the presence of 30 µM Ca2+/calmodulin and phosphorylation reaction 
was then performed in the presence or in the absence of EGTA. STOP and CaMKII were analyzed by 
Western blot using antibodies as in (A). 
 
Fig. 3. Microtubule-binding assay. CE fractions were subjected (CE-P) or not (CE) to phosphorylation 
and were next incubated in the presence of taxol-stabilized microtubules (lanes 1-2 and 5-6) or 
without microtubules (lanes 3-4 and 7-8). After centrifugation, equal amount of the pellets (P) and 
supernatants (S) were separated by SDS/PAGE and analyzed by western blot to detect the presence of 
N-STOP. 
 
Fig. 4. Phosphorylated N-STOP antibodies. CE fractions (CE) were subjected either to 
phosphorylation reaction (CE-P) or to alkaline phosphatase treatment (CE-AP). Equal amount of 
proteins from fractions CE, CE-P and CE-AP were analyzed in the same immunoblots, with total N-
STOP antibody mAb 175, phosphorylated N-STOP antibodies P2 (S198), P4 (S491) or P1 (S139). All 
phosphorylated N-STOP antibodies are highly specific of the phosphorylated form of N-STOP. 
 
Fig. 5. Phosphorylated N-STOP (N-STOP-P) in differentiating neurons. A-B, Distribution of STOP 
proteins in cultured mouse hippocampal neurons after 12 days of differentiation in vitro, showing 
either neuritic network (left panels) or branching points (right panels). (A) Double N-STOP/ tubulin 
or phosphorylated N-STOP/tubulin staining was performed using STOP antibodies (mAb 175 for N-
STOP and P2 antibody for phosphorylated STOP). Merge is the result of tubulin labeling in red and 
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STOP (STOP or STOP-P) labeling in green. B, Double immunostaining of either N-STOP/ actin or 
phosphorylated STOP/actin were performed. Merge is the result of actin labeling in red and STOP 
(STOP or STOP-P) labeling in green. C, Triple immunostaining of phosphorylated N-STOP, tubulin 
and actin, using antibodies as in (A) and (B), after cytochalasin treatment.D, Effect of neuronal 
activation: Phosphorylated STOP staining was quantified in both control neurons and neurons 
exposed to glutamate prior to fixation, using equal exposure time during image acquisition, in both 
conditions. 130 spikes from 30 independent neurons from three independents experiments were 
selected in both control and activated neurons. A region of interest was traced around each spike, and 
the maximum fluorescence intensity value (a.u.) was measured in each region. Values were averaged 
for each condition and plotted on the figure (mean ±s.e.m.). *** p ≤ 0.001 t test. E, Double 
immunostaining of phosphorylated N-STOP and actin after incubation of the neuronal culture with the 
inhibitor of CaMKinases, KN62 for 8 h. Antibodies and merge were as in (B). Bar: 20µm. 
 
Fig. 6. Actin binding assay. Actin binding assays were performed starting with various amount of G-
actin (1 µM, 6 µM and 15 µM) and with N-STOP (from CE fraction or after affinity purification). A, 
Actin polymerization. Various amount of G-actin were polymerized in the presence of CE fraction 
and then centrifuged. Supernatant and pellets were separated by 7.5% SDS PAGE and were stained 
with Commassie blue, showing no detectable amount of actin in the supernatant. B, Analysis of N-
STOP and CaMKII binding to F-Actin. CE fraction: various amounts of G-actin (1 µM, 6 µM and 15 
µM) were polymerized in the presence of CE fraction containing N-STOP and CaMKII proteins, and 
then centrifuged. Equal amounts of supernatants and pellets were separated by 7.5% SDS PAGE, 
transferred on nitrocellulose and blotted with mAb 175 or anti CaMKII antibody. Affinity-purified N-
STOP: G-actin (1 µM and 15 µM) was polymerized in the presence of affinity purified N-STOP and 
then centrifuged. Equal amounts of supernatant and pellet were analyzed as above. C, Analysis of N-
STOP and CaMKII binding to F-Actin after phosphorylation. Various amounts of G-actin (1 µM, 6 
µM and 15 µM) were polymerized in the presence of phosphorylated CE fraction and then 
centrifuged. Equal amounts of supernatants and pellets were analyzed as in (B). 
 
Fig. 7. Phosphorylated STOP in differentiated neurons. Distribution of STOP proteins in cultured 
mouse hippocampal neurons after 45 days of differentiation in vitro. A, Double immunostaining of N-
STOP/synapsin or phosphorylated STOP/synapsin (mAb 175 for N-STOP and P2 antibody for 
phosphorylated STOP). Merge is the result of synapsin labeling in red and STOP (N-STOP or STOP-
P) labeling in green. B, Double immunostaining of phosphorylated STOP/synapsin and of 
phosphorylated STOP/homer. Merge is the result of either synapsin or homer labeling in red, and 
STOP-P labeling in green. 
 









